AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Clinical Impact of Sodium-Glucose Cotransporter-2 Inhibitor Therapy at Discharge in Patients with Acute Myocardial Infarction-Related Cardiogenic Shock Requiring Mechanical Circulatory Support
By Taniguchi G, Fujino T, Misumi K et al.
Background: Recent clinical trials have suggested potential benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2i) following acute myocardial infarction (AMI). However, patients with cardiogenic shock requiring mechanical circulatory support (MCS) were excluded from these trials, leaving their effectiveness in this population uncertain. We investigated the association between discharge SGLT2i therapy and 180-day outcomes in patients with AMI-related cardiogenic shock (AMICS) requiring MCS. Methods: We analyzed the Q-HEART Retrospective Shock Registry (6 hospitals, 2020-2025). Consecutive AMI patients requiring MCS, including intra-aortic balloon pump, venoarterial extracorporeal membrane oxygenation, or Impella, were enrolled. Exclusion criteria were dialysis dependence, in-hospital death, or missing data. Patients who received SGLT2i therapy at discharge were included in the SGLT2i group, and the others were in the non-SGLT2i group. The primary endpoint was the 180-day composite of all-cause mortality and heart failure rehospitalization. Propensity score matching (PSM) was performed using age, sex, left ventricular ejection fraction (LVEF), body mass index (BMI), estimated glomerular filtration rate (eGFR), and guideline-directed medical therapy. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression. Results: Among 523 patients with AMICS requiring MCS in this registry, 314 survived to discharge and were eligible for this study (SGLT2i group, n=119 [38%]; non-SGLT2i group, n=195 [62%]). Median age was 72 years and 78% were male. Compared with the non-SGLT2i group, the SGLT2i group had a higher prevalence of diabetes (58% vs 32%, p<0.001), a higher proportion of male sex (85% vs 74%, p=0.028), and lower LVEF (43% vs 48%, p<0.001). In the overall cohort, Kaplan-Meier analysis demonstrated higher 180-day event-free survival in the SGLT2i group compared with the non-SGLT2i group (96% vs 88%; log-rank p=0.031). Cox proportional hazards regression confirmed the association between SGLT2i use and reduced risk of the 180-day composite endpoint (univariate: HR 0.36, 95% CI 0.14-0.95, p=0.038; adjusted for age and sex: HR 0.34, 95% CI 0.13-0.90, p=0.030). After PSM (72 matched pairs), 180-day event-free survival in the SGLT2i group was higher compared with the non-SGLT2i group (96% vs. 80%; log-rank p=0.004). Cox proportional hazards regression demonstrated a lower risk of the 180-day composite endpoint in the SGLT2i group (HR 0.20, 95% CI 0.06-0.60, p=0.004). Conclusion: Among AMICS patients requiring MCS, initiation of SGLT2i therapy at discharge was associated with improved 180-day clinical outcomes. These findings suggest that SGLT2i therapy may benefit patients with AMICS requiring MCS, a population historically excluded from post-AMI trials, and support further prospective investigation.